Several ongoing clinical trials are investigating the role of immunotherapy in advanced ovarian cancer (i.e., pembrolizumab and nivolumab are anti-PD-1 monoclonal antibodies; avelumab, atezolizumab, and durvalumab inhibit PD-L1) [74]; at present date, none of the major international guidelines have incorporated immunotherapy into their standard treatment recommendations for advanced ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.